• 01
  • 02
  • 03
profile Photo

About Conference

Dear Colleagues, 

Apex Global Meetings is delighted to announce and cordially invites all the participants across the globe to attend 2nd Global Summit Conference Neurology and Neurological Disorders at (NEURO2025) which will be taking place during July 07-09, 2025 at Munich, Germany. The theme of the conference highlights "Unveiling Neurological Horizons: From Cutting-Edge Imaging to Ethical Frontiers in Neurotechnology". Scientific Tracks designed for this conference will enable the attendees and participants to learn extremes. 

NEURO2025 aims to gather the renowned scientists, young and brilliant researchers, academicians, experts, healthcare professionals, business delegates, and exceptional student communities across the globe under one roof and organize a healthy discussion so that the researchers and authors can present their work at the conference. NEURO2025 objective is to provide a comprehensive global forum for experts and participants from academia to exchange ideas and present results of on-going research in the most state-of-the-art areas of Neurology and neurological disorders and allied topics. It will be hosting a forum of plenary, keynote, Invited lectures and oral/ poster presentations. 

We accept this gathering will be an exceptionally remunerating instructive and collaborative occasion for the attendees. 

We look forward to your valuable presence at NEURO2025 in Munich, Germany. 

Regards,
Poojitha A | Event Manager
NEURO2025
Apex Global Meetings
Contact: +91-8977610040
Email: neuro@apexglobalmeetings.com

Parkinson Disease

Spinal Disorders

Genomic Medicine

Alzheimer

Brain Cancer

Stroke/Cerebrovascular Disease

Neurodegeneration and Stem Cell Therapy

Clinical Neurophysiology

Brain Injury and Behavioral Neuroscience

Paediatric Neurology and Epilepsy

Geriatric Psychiatry and Neurology

Brain Pathology and Oncology Research

Neuroscience and Artificial Intelligence

Neurodermatology

Brain-Computer Interfaces (BCIs)

Pain management

Neuromuscular disease

Neurosurgery

Neurobiology

Migraine and Headache Disorders

Multiple Sclerosis

Neurocardiology

Stroke/Cerebrovascular Disease

Neuroimmunology

The neurology clinical trials market is forecasted to experience a Compound Annual Growth Rate (CAGR) of 4.35% during the period spanning from 2022 to 2027. The emergence of Covid-19 had a profound impact on healthcare globally, particularly affecting older populations and individuals with underlying health conditions, including neurological diseases. Given that neurological conditions are a significant contributor to mortality among older adults, the pandemic heightened concerns, especially considering the challenges individuals with conditions like dementia face in adhering to preventive measures.

The disruption caused by the pandemic extended to ongoing clinical trials, leading to delays in enrollment, data collection, and analysis. Research indicates that a considerable number of trials with neurological indications were affected, particularly those related to pain, mental health, and addiction. These setbacks are anticipated to impede market growth during the forecast period.

However, despite these challenges, several factors are expected to drive growth in the neurology clinical trials market. This includes an increase in the number of companies conducting trials, the rising prevalence of neurological diseases, and augmented investments in research and development (R&D), both from private and public sectors.

Alzheimer's Disease, in particular, stands out as a significant driver of demand for neurology clinical trials. The condition remains a critical challenge in neuroscience, characterized by abnormal protein accumulation in and around brain cells. While the exact triggers of Alzheimer's Disease are yet to be fully understood, factors such as age, family history, and certain health conditions are known to increase susceptibility.

The approval of multiple drugs by regulatory bodies like the US Food and Drug Administration (FDA) for Alzheimer's treatment underscores the ongoing efforts in drug development. Clinical trials for Alzheimer's treatment are also witnessing a surge, with numerous agents undergoing various phases of testing, targeting cognitive enhancement, disease modification, and management of neuropsychiatric symptoms.

In conclusion, while stringent regulatory demands, high failure rates, and escalating trial costs pose challenges, the neurology clinical trials market is poised for growth. The expansion of Alzheimer's Disease research and the broader spectrum of neurological conditions are expected to fuel this growth despite the setbacks caused by the Covid-19 pandemic.

Important Dates


Abstract Submission Deadline

April 28, 2025

Earlybird Registration Deadline

April 15, 2025

Standard Registration Deadline

May 26, 2025

Onspot Registration

July 07, 2025

Media Partners

Registration

Registration Includes

  • Access to all conference sessions, poster and exhibition area
  • Conference kit including name tag, program booklet and Abstracts book
  • 2 Coffee breaks and lunch for all the event days of the conference
  • Certificate of participation from Conference chair/ Session chair
  • Access to the all scientific sessions
  • Access to Business Development Sessions and Global Networking Session
Read More

Benefits of Joining Conference

  • Encouraged to publish full length articles in Supporting Journals with discounted APC charges
  • Best Oral, Poster and Young Research Forum (YRF) presentation awards
  • Get Opportunity to Collaborate with future Apex Global Meetings
  • Avail Group Booking Discounts
  • All the articles presented in this conference will be considered for publications as per their quality in SCI / SCIE / SCOPUS / Peer Reviewed journals of Springer and / or other publishers
Read More

Group Booking Discounts

Groups of three or more will receive a Special discount by using the group code. If you have any queries, please contact us at or call

neuro@apexglobalmeetings.com